1,721,095 research outputs found
Quality of life impact of childhood skin conditions measured using the children’s dermatology life quality index (CDLQI): a meta-analysis
Full text linkBackground: The Children’s Dermatology Life Quality Index (CDLQI) is the most widely used instrument for measuring the impact of skin disease on quality of life (QoL) in children.
Objective: Provide a meta-analysis of all published quality of life (QoL) scores for a range of childhood skin conditions.
Methods: Studies using the Children’s Dermatology Life Quality Index (CDLQI) questionnaire to measure QoL in skin conditions were identified by searching Medline and Embase from January 1995 (CDLQI creation) to December 2014. Studies were grouped according to condition and baseline scores were combined using meta-analysis.
Results: 67 studies using the CDLQI met the inclusion criteria. The overall estimated CDLQI scores for conditions reported more than once were: atopic eczema (Point Estimate 8.5 (95% CI 7.1-9.8), number of studies = 38, score range = 0-29), acne (5.3 (1.9-8.5), n=5, 0-30), alopecia (3.1 (0-7.7), n=2, 0-6), molluscum contagiosum (3.5 (0.6-6.7), n=5, 0-27), psoriasis (8.0 (3.9-12.1), n=6, 0-29), scabies (9.2 (0.0-20.3), n=2, 1-26), urticaria (7.1 (0-15.4), n=2, 0-22), vitiligo (6.5 (0.7-12.2), n=2, 0-20), and warts (2.9 (0-5.8), n=4, 0-16). Overall, the mean effect on QoL (weighted average CDLQI score 4.6 (95% CI 3.9 to 5.4)) for children with these conditions was small. However, many children were found to experience a very large impact on QoL (34% of children with atopic eczema, 10% with molluscum contagiosum and 1 - 5% with acne) in studies where the distributions of scores were provided.
Conclusions: Most skin conditions in children have a “small” mean effect on quality of life. However, the range is large and a significant proportion of children with many common skin conditions will experience a very large effect on quality of life
Guest Editorial: How to Succeed in Medicine
Full text linkIn this guest editorial, Professor Andrew Y Finlay discusses how to succeed in medicine. As a Professor of Dermatology, pioneer of the Dermatology Life Quality Index and co-founder of the Journal of Dermatological Treatment, alongside many other achievements, his career demonstrates the breadth and variety a career in medicine can offer. His editorial provides valuable insights and practical advice for career development, as well as methods for contributing to the improvement of clinical care
Measurement of disease activity and outcome in atopic dermatitis [review]
No full textMany different systems have been proposed for the recording and measurement of disease activity in atopic dermatitis (AD). This review describes the techniques that have been used and published in recent years for clinical evaluation and for objective measurement of AD, as well as for recording its effects on quality of life. Recommendations are made concerning which methods should be used
Quality of life measurement in dermatology: a practical guide [review]
No full textThe purpose of this review is to guide clinicians and researchers who wish to use quality of life (QOL) measures in dermatology. Definitions of key words are given, with a guide to descriptions of the adverse effects of skin disease. The reasons for measuring QOL in dermatology are explained, with descriptions of the use of disease specific, dermatology specific, general health and utility measure questionnaires. Measurement methods of QOL in children and the family impact of skin disease are also described. There is advice about how to choose which method to use, and where to find the questionnaires
Current severe psoriasis and the Rule of Tens
No full textThis review addresses the problems of defining severity of psoriasis. Concepts of severity depend on the timescale perspective from which judgement is made. Measurement needs to include assessment of signs, impact on the patient's life and the history of the disease. The concept of severity in relationship to quality of life measurement scores has been defined, so it is now possible to postulate a standard, easily remembered concept to help define ‘severe psoriasis’ in the clinic. The proposed Rule of Tens for current severe psoriasis from the clinician's viewpoint is: ‘Current Severe Psoriasis = Body Surface Area involved > 10% or Psoriasis Area and Severity Index score > 10 or Dermatology Life Quality Index score > 10’
Dowling Oration 2000. Dermatology patients: what do they really need?
No full textDermatology services must be organized to meet the needs of patients. These needs change as society changes and medical knowledge increases. Considerable insight into the true needs of individual and groups of patients can be gained from the use of quality of life measures. Patients with widespread inflammatory skin disease are most severely handicapped by their skin disease and can be most helped by dermatology services. It is essential that such patients be given priority in the delivery of dermatological care. Where necessary, protected clinic time and specialist support services should be created to ensure that such patients are not adversely affected by pressures to review patients in other diagnostic groups
Global overview of Lamisil [Review]
No full textTerbinafine (Lamisil) is a new antifungal drug which is now available in many countries worldwide. This review seeks to summarize why terbinafine is of interest and how well it reaches its target sites--the stratum corneum and nail plate. The diseases in which it is potentially effective are described and evidence that terbinafine is of value in these diseases is cited. There are very few effective drugs which do not have some potential for producing side-effects and these are discussed
- …
